Changes in Monoamine Levels in BALB/c and 57Bl/6N Mice in Response to Acute Stress with Different Controllability
- Authors: Kasabov K.A.1, Shakhovtsev D.A.2, Malyshev N.V.2, Konstantinov M.A.2, Narkevich V.B.1, Kudrin V.S.1, Anderzhanova E.A.1,3
-
Affiliations:
- V. V. Zakusov Research Institute of Pharmacology
- N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation
- University Hospital Bonn, Clinic of Psychiatry and Psychotherapy
- Issue: Vol 167, No 5 (2019)
- Pages: 610-615
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/241961
- DOI: https://doi.org/10.1007/s10517-019-04581-2
- ID: 241961
Cite item
Abstract
The severity and specificity of CNS disturbances resulting from negative psychoemotional experience are determined by not only genetically determined stress sensitivity, but also epigenetic factors; among the latter, the context of stress exposure, e.g. stress controllability is considered. We examined the effect of controllability factor on behavioral and neurochemical parameters of acute stress in the elevated plus maze test. The situations of controllable and uncontrollable stress were modeled by allowing or restricting mice in their choice for closed arms during testing in the maze. The anxiety level of inbred BALB/c and C57Bl/6N mice was assessed and the levels and monoamine turnover in the medial prefrontal cortex, hippocampus, amygdala, and hypothalamus were measured. It was found that the decrease in stress controllability suppresses explorative activity in mice; the behavioral and neurochemical differences between the two strains are not constant feature and depend on stress controllability; serotoninergic and dopaminerigic neurotransmission in the hypothalamus can be a signal to discriminate stress controllability in the brain.
About the authors
K. A. Kasabov
V. V. Zakusov Research Institute of Pharmacology
Author for correspondence.
Email: kirkasabov@gmail.com
Russian Federation, Moscow
D. A. Shakhovtsev
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation
Email: kirkasabov@gmail.com
Russian Federation, Moscow
N. V. Malyshev
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation
Email: kirkasabov@gmail.com
Russian Federation, Moscow
M. A. Konstantinov
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation
Email: kirkasabov@gmail.com
Russian Federation, Moscow
V. B. Narkevich
V. V. Zakusov Research Institute of Pharmacology
Email: kirkasabov@gmail.com
Russian Federation, Moscow
V. S. Kudrin
V. V. Zakusov Research Institute of Pharmacology
Email: kirkasabov@gmail.com
Russian Federation, Moscow
E. A. Anderzhanova
V. V. Zakusov Research Institute of Pharmacology; University Hospital Bonn, Clinic of Psychiatry and Psychotherapy
Email: kirkasabov@gmail.com
Russian Federation, Moscow; Bonn